246 related articles for article (PubMed ID: 22957898)
21. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
[TBL] [Abstract][Full Text] [Related]
22. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
Paes FM; Kalkanis DG; Sideras PA; Serafini AN
Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
[TBL] [Abstract][Full Text] [Related]
25. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.
Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK
Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
[TBL] [Abstract][Full Text] [Related]
27. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
28. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
[TBL] [Abstract][Full Text] [Related]
29. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
[TBL] [Abstract][Full Text] [Related]
30. Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma.
Mody RJ; Bui C; Hutchinson RJ; Frey KA; Shulkin BL
Leuk Lymphoma; 2007 Apr; 48(4):699-707. PubMed ID: 17454627
[TBL] [Abstract][Full Text] [Related]
31. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma.
Bednaruk-Młyński E; Pieńkowska J; Skórzak A; Małkowski B; Kulikowski W; Subocz E; Dzietczenia J; Zalewska M; Leśniewski-Kmak K; Zaucha R; Wróbel T; Zaucha JM
Leuk Lymphoma; 2015 Feb; 56(2):377-82. PubMed ID: 24794802
[TBL] [Abstract][Full Text] [Related]
32. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
J Comput Assist Tomogr; 2017 Jan; 41(1):98-103. PubMed ID: 27560022
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
35. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
Akkas BE; Vural GU
Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
[TBL] [Abstract][Full Text] [Related]
36. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
37. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
38. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
40. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
Bhojwani D; McCarville MB; Choi JK; Sawyer J; Metzger ML; Inaba H; Davidoff AM; Gold R; Shulkin BL; Sandlund JT
Br J Haematol; 2015 Mar; 168(6):845-53. PubMed ID: 25382494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]